ElectraDx.

ElectraDx, based in the USA, develops and markets advanced diagnostic testing solutions aimed at enhancing healthcare accessibility and affordability through innovative devices that provide lab-quality results at the point of care. Founded in 2023, ElectraDx specializes in diagnostic testing solutions. The company is headquartered in Dover, US. It completed its first deal in November 2025, raising funds to support its growth strategy.

The founder's history is currently not available. ElectraDx specializes in advanced diagnostic testing solutions designed to enhance healthcare accessibility and affordability. Their core offerings include innovative devices and technologies that deliver precise, lab-quality results at the point of care and within home environments. These products aim to address critical healthcare needs, such as early detection of diseases and effective condition management, making them essential tools for both healthcare providers and patients.

The company targets a diverse client base, including hospitals, clinics, and individual consumers, with a focus on expanding healthcare access across various geographical markets such as North America, Europe, and select regions in Asia. ElectraDx's intuitive devices are designed to require no special training, making them user-friendly for a broad audience, thereby ensuring that advanced testing solutions can reach underserved communities. ElectraDx generates revenue through a structured model that includes direct sales to healthcare providers and partnerships with retailers and wholesalers. Their flagship products are positioned to cater to both B2B and direct-to-consumer markets, ensuring a wide distribution network.

Transactions typically occur at the individual product level, with customers purchasing their testing devices as needed, complemented by potential subscription services for ongoing support and consumables. The pricing strategy is designed to be ultra-low, aiming to minimize barriers for communities worldwide. Specific pricing information and detailed transaction structures are closely aligned with the company's mission to transform healthcare accessibility. In November 2025, ElectraDx raised an undisclosed amount in SERIES B funding from new investor TAUNS Laboratories, Inc.

This funding will be utilized to accelerate the advancement and expansion of point-of-care testing (POCT), enabling the delivery of innovative solutions that excel in performance, affordability, and convenience. The company plans to introduce new products that further enhance diagnostic capabilities and expand into additional geographical markets, although specific regions and launch dates have yet to be disclosed.